ME02417B - Kondenzovani derivati imidazola koji su korisni kao ido inhibitori - Google Patents

Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Info

Publication number
ME02417B
ME02417B MEP-2016-82A MEP201682A ME02417B ME 02417 B ME02417 B ME 02417B ME P201682 A MEP201682 A ME P201682A ME 02417 B ME02417 B ME 02417B
Authority
ME
Montenegro
Prior art keywords
imidazole derivatives
derivatives useful
ido inhibitors
fused imidazole
fused
Prior art date
Application number
MEP-2016-82A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Mario Mautino
Sanjeev Kumar
Jesse Waldo
Firoz Jaipuri
Tanay Kesharwani
Xiaoxia Zhang
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of ME02417B publication Critical patent/ME02417B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2016-82A 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori ME02417B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors
EP12715295.7A EP2697227B1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (1)

Publication Number Publication Date
ME02417B true ME02417B (me) 2016-09-20

Family

ID=45976556

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-82A ME02417B (me) 2011-04-15 2012-04-12 Kondenzovani derivati imidazola koji su korisni kao ido inhibitori

Country Status (30)

Country Link
US (5) US9260434B2 (enExample)
EP (3) EP3348558A1 (enExample)
JP (4) JP2014511876A (enExample)
KR (1) KR102164443B1 (enExample)
CN (2) CN103547579B (enExample)
AU (4) AU2012242871C1 (enExample)
BR (1) BR112013026494A2 (enExample)
CA (1) CA2833296C (enExample)
CL (1) CL2013002990A1 (enExample)
CO (1) CO6862146A2 (enExample)
CY (1) CY1117440T1 (enExample)
DK (2) DK2697227T3 (enExample)
ES (2) ES2660831T3 (enExample)
HK (1) HK1256355A1 (enExample)
HR (2) HRP20160369T1 (enExample)
HU (2) HUE027316T2 (enExample)
IL (3) IL228862A (enExample)
LT (1) LT3018132T (enExample)
ME (1) ME02417B (enExample)
MX (1) MX340442B (enExample)
NO (1) NO2694640T3 (enExample)
NZ (2) NZ708090A (enExample)
PE (2) PE20181023A1 (enExample)
PL (2) PL3018132T3 (enExample)
PT (1) PT3018132T (enExample)
RS (2) RS54723B1 (enExample)
RU (2) RU2613579C2 (enExample)
SI (2) SI3018132T1 (enExample)
SM (1) SMT201600130B (enExample)
WO (1) WO2012142237A1 (enExample)

Families Citing this family (282)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (enExample) * 2011-04-15 2018-03-17
EP2729180B1 (en) 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
BR112015022588A2 (pt) 2013-03-14 2017-07-18 Newlink Genetics Corp composto, composição farmacĂȘutica, e, mĂ©todo para tratamento de imunossupressĂŁo em um indivĂ­duo
EA201591610A1 (ru) * 2013-03-14 2015-12-30 ĐšŃƒŃ€Đ°ĐŽĐ”ĐČ Đ€Đ°Ń€ĐŒĐ° ПраĐčĐČот ЛтЮ. Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ĐșĐžĐœŃƒŃ€Đ”ĐœĐžĐœĐŸĐČĐŸĐłĐŸ путо
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (zh) * 2013-08-06 2015-06-03 äżĄćźžç”Ÿç‰©ćŒ»èŻïŒˆäžŠæ”·ïŒ‰æœ‰é™ć…Źćž 侀种3-æ°Ż-7(5)-æșŽè‹Żćč¶ćŒ‚æ¶ć”‘çš„ćˆæˆæ–čæł•
EA201990240A1 (ru) 2013-12-24 2019-06-28 Đ‘Ń€ĐžŃŃ‚ĐŸĐ»-ĐœĐ°Đ”Ń€Ń ĐĄĐșĐČОбб ĐšĐŸĐŒĐżĐ°ĐœĐž ĐĐŸĐČыД троцоĐșлОчДсĐșОД ŃĐŸĐ”ĐŽĐžĐœĐ”ĐœĐžŃ ĐČ ĐșачДстĐČĐ” ĐżŃ€ĐŸŃ‚ĐžĐČĐŸŃ€Đ°ĐșĐŸĐČых срДЎстĐČ
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
KR20170044144A (ko) 2014-09-05 2017-04-24 메넎큏 파텐튾 êČŒì— ëȠ하 암 ìč˜ëŁŒë„Œ 위한 ìžëŒì•„ëŻŒ-2,3-디옄시êČŒë‚˜ì œ(ido) êžží•­ì œëĄœì„œ ì‹œíŽëĄœí—„ì‹€-에틞 ìč˜í™˜ëœ 디아자- 및 íŠžëŠŹì•„ìž-íŠžëŠŹì‹œíŽëŠ­ í™”í•©ëŹŒ
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
CA3220466A1 (en) 2014-10-29 2016-05-06 Bicyclerd Limited Bicyclic peptide ligands specific for mt1-mmp
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
KR20170122799A (ko) 2015-03-02 2017-11-06 늏êȔ 파마슈티ìčŒìŠ€, ìžíŹ. TGF-ÎČ ì–”ì œì œ
US10399933B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
KR20170137165A (ko) * 2015-04-10 2017-12-12 ëČ ìŽì§„ 엘티디 ìžëŒì•„ëŻŒ 및/또는 튞늜토판 2,3-디옄시êČŒë‚˜ì•„ì œëĄœì„œ 신규한 5 또는 8-ìč˜í™˜ëœ ìŽëŻžë‹€ìĄ°[1,5-a]í”ŒëŠŹë”˜
EP3283488A4 (en) * 2015-04-12 2018-10-24 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
HUE053903T2 (hu) 2015-04-13 2021-07-28 Five Prime Therapeutics Inc KombinĂĄciĂłs terĂĄpia rĂĄk ellen
AU2016250976B2 (en) 2015-04-21 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
WO2016183115A1 (en) 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 æˆéƒœæ”·ćˆ›èŻäžšæœ‰é™ć…Źćž äž€ç§æ°˜ä»Łçš„idoæŠ‘ćˆ¶ć‰‚ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œç”šé€”
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105037371A (zh) * 2015-06-30 2015-11-11 è„żćŽć€§ć­Š äž€ç§æ°˜ä»Łçš„ćČ據èƒș-2,3-ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN116196426A (zh) 2015-07-16 2023-06-02 ç™ŸæŹ§è‚ŻæČ»ç–—æœ‰é™ć…Źćž æČ»ç–—ç™Œç—‡çš„ç»„ćˆç‰©ćŠæ–čæł•
MX2018001014A (es) 2015-07-24 2018-05-23 Newlink Genetics Corp Sales y profarmacos de 1-metil-d-triptofano.
WO2017019757A1 (en) 2015-07-28 2017-02-02 Bristol-Myers Squibb Company Tgf beta receptor antagonists
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
JP2018525415A (ja) 2015-08-25 2018-09-06 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒŽïœ‡ïœ†ăƒ™ăƒŒă‚żć—ćźčäœ“ă‚ąăƒłă‚żă‚Žăƒ‹ă‚čト
CN106478634B (zh) * 2015-09-01 2020-05-22 ć°šćŽćŒ»èŻç§‘æŠ€(æ±Ÿè„ż)æœ‰é™ć…Źćž 皠搈ć’Șć”‘ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ć’Œç”šé€”
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
JP6936221B2 (ja) 2015-11-02 2021-09-15 ăƒ•ă‚Ąă‚€ăƒ– ăƒ—ăƒ©ă‚€ăƒ  ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŁïœ„ïŒ˜ïŒçŽ°èƒžć€–ăƒ‰ăƒĄă‚€ăƒłăƒăƒȘペプチドべ、がんæČ»ç™‚ă§ăźăă‚Œă‚‰ăźäœżç”š
WO2017080934A1 (en) * 2015-11-09 2017-05-18 F. Hoffmann-La Roche Ag Screening assay to identify id01 and/or tdo modulators
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
JP7349787B2 (ja) 2015-11-23 2023-09-25 ăƒ•ă‚Ąă‚€ăƒŽ ăƒ—ăƒ©ă‚€ăƒ  ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚Ż 癌æČ»ç™‚ă«ăŠă‘ă‚‹ïœ†ïœ‡ïœ†ïœ’ïŒ’é˜»ćźłć‰€ć˜ç‹ŹăŸăŸăŻć…ç–«ćˆșæż€ć‰€ăšăźç”„ăżćˆă‚ă›
US10450318B2 (en) 2015-12-15 2019-10-22 Bristol-Myers Squibb Company CXCR4 receptor antagonists
JP7227005B2 (ja) * 2015-12-24 2023-02-21 ă‚žă‚§ăƒăƒłăƒ†ăƒƒă‚ŻïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒŽïœ„ïœïŒ’é˜»ćźłć‰€
CN107056785B (zh) * 2016-01-02 2021-06-22 æ­ć·žè‹±ćˆ›ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž 䜜äžșido撌tdoæŠ‘ćˆ¶ć‰‚çš„æ‚çŽŻćŒ–ćˆç‰©
EP3400226A1 (en) 2016-02-02 2018-11-14 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
US10487088B2 (en) 2016-02-19 2019-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound serving as immunomodulator
EP3416725A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
CN108884104B (zh) * 2016-02-19 2021-01-15 æ­Łć€§ć€©æ™ŽèŻäžšé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 䜜äžșć…ç–«è°ƒèŠ‚ć‰‚çš„äž‰ćč¶çŽŻćŒ–ćˆç‰©
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
KR20230038311A (ko) 2016-03-04 2023-03-17 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 항-cd73 항ìČŽì™€ì˜ ìĄ°í•© 요ëȕ
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CN105732643A (zh) * 2016-04-18 2016-07-06 è‹ć·žć€§ć­Š äž€ç§ć¶è”ç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠćœšćˆ¶ć€‡idoé…¶æŠ‘ćˆ¶ć‰‚ć’Œéžç”Ÿäœ“æŠ—ç‚ŽèŻç‰©äž­çš„ćș”甚
CN107312005B (zh) * 2016-04-27 2021-12-17 äžŠæ”·çż°æŁźç”Ÿç‰©ćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć…·æœ‰ido/tdoæŠ‘ćˆ¶æŽ»æ€§çš„çš ćˆć’Șć”‘èĄç”Ÿç‰©ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚
CN109348714A (zh) 2016-05-04 2019-02-15 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„æŠ‘ćˆ¶ć‰‚ćŠć…¶äœżç”šæ–čæł•
KR20190004743A (ko) 2016-05-04 2019-01-14 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
WO2017192813A1 (en) 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20190003687A (ko) 2016-05-04 2019-01-09 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
KR20190003686A (ko) 2016-05-04 2019-01-09 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ 얔제제 및 귞의 ì‚Źìš© ë°©ëȕ
CN109790143A (zh) 2016-05-10 2019-05-21 C4ćŒ»èŻć…Źćž 甹äșŽé¶è›‹ç™œé™è§Łçš„èƒșèżžæŽ„çš„c3-戊äșŒé…°äșšèƒșé™è§Łć†łćźšć­äœ“
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN105902542A (zh) * 2016-05-16 2016-08-31 ćŒ é˜ł äž€ç§ć¶è”ç‰©ćœšćˆ¶ć€‡æČ»ç–—ćżƒèĄ€çźĄç–Ÿç—…èŻç‰©äž­çš„ćș”甚
CN107383012B (zh) * 2016-05-16 2021-09-28 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž 搫äșŒçŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556316B (zh) * 2016-06-30 2021-11-12 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
CN106957318B (zh) * 2016-05-19 2019-12-10 äž­ć›œç§‘ć­Šé™ąäžŠæ”·æœ‰æœșćŒ–ć­Šç ”ç©¶æ‰€ çš ćˆć€šçŽŻćČć“šć•‰ćŒ–ćˆç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ă€èŻç‰©ç»„ćˆç‰©ćŠćș”甚
JP7090034B2 (ja) 2016-05-20 2022-06-23 ă‚¶ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ シカゎ ćŒ–ć­Šç™‚æł•ă€æš™çš„ç™‚æł•ă€ć…‰ç·šćŠ›ć­Šç™‚æł•ă€ć…ç–«ç™‚æł•ćŠăłăă‚Œă‚‰ăźä»»æ„ăźç”„ăżćˆă‚ă›ăźăŸă‚ăźăƒŠăƒŽçȒ歐
AR108586A1 (es) 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) * 2016-06-11 2024-06-07 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«æĄ„çŽŻçš„ć’Șć”‘é†‡èĄç”Ÿç‰©
CN107556315B (zh) * 2016-06-30 2021-08-31 éČć—ćˆ¶èŻé›†ć›ąè‚Ąä»œæœ‰é™ć…Źćž ć«ć››ć…ƒçŽŻçš„ć’Șć”‘èĄç”Ÿç‰©
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 䞊攷èżȘèŻșćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ć€šçŽŻćŒ–ćˆç‰©ă€ć…¶èŻç‰©ç»„ćˆç‰©ćŠćș”甚
CN107698594A (zh) * 2016-08-09 2018-02-16 è‹ć·žć›œćŒĄćŒ»èŻç§‘æŠ€æœ‰é™ć…Źćž ćČ據èƒș23â€‘ćŒćŠ æ°§é…¶æŠ‘ćˆ¶ć‰‚ćŠć…¶ćœšèŻć­Šäž­çš„ç”šé€”
US11351164B2 (en) 2016-08-26 2022-06-07 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 ćčżć·žćż…莝ç‰čćŒ»èŻæŠ€æœŻæœ‰é™ć…Źćž 搫ć’Șć”‘çš ćˆäž‰çŽŻç±»ćŒ–ćˆç‰©ćŠć…¶ćș”甚
TW201815766A (zh) 2016-09-22 2018-05-01 çŸŽć•†æ™źé›·èŸ›è‚Żć…Źćž ç”šæ–Œïœ‰ïœ„ïœćŠïœ”ïœ„ïœèȘżçŻ€äč‹ćŒ–ćˆç‰©ćŠæ–čæł•ä»„ćŠć…¶é©æ‡‰ç—‡
CN109952300B (zh) 2016-09-24 2022-01-18 ç™Ÿæ”Žç„žć·žæœ‰é™ć…Źćž 5或8-ć–ä»Łçš„ć’Ș攑ćč¶[1,5-a]搥敶
AU2017343780B2 (en) 2016-10-13 2023-08-31 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
TW201815793A (zh) * 2016-10-21 2018-05-01 æ±Ÿè˜‡æ†ç‘žé†«è—„è‚Ąä»œæœ‰é™ć…Źćž 侀繼ć’Ș攑侩異ćČć“šéĄžèĄç”Ÿç‰©çš„éŠé›ąéčŒçš„ç”æ™¶ćœąćŒćŠć…¶èŁœć‚™æ–čæł•
TW201815417A (zh) * 2016-10-21 2018-05-01 è˜‡ć·žç››èżȘäșžç”Ÿç‰©é†«è—„æœ‰é™ć…Źćž ïŒ°ïœ„ïŒïŒ‘æŠ—é«”èˆ‡ïœ‰ïœ„ïœæŠ‘ćˆ¶ćŠ‘èŻćˆćœšèŁœć‚™æŠ—è…«ç˜€çš„è—„ç‰©äž­çš„ç”šé€”
WO2018083635A2 (en) 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
CN106474468B (zh) * 2016-11-23 2020-03-27 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŒ»ć­Šç”Ÿç‰©ć­Šç ”ç©¶æ‰€ äž€ç§ć€ćˆäœć‰‚ă€ć«èŻ„ć€ćˆäœć‰‚çš„ç–«è‹—ćŠç–«è‹—çš„ćˆ¶ć€‡æ–čæł•
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
US10604529B2 (en) 2016-12-20 2020-03-31 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
PE20191541A1 (es) 2016-12-22 2019-10-23 Calithera Biosciences Inc Composiciones y metodos para inhibir la accion de la arginasa
CN108239091B (zh) * 2016-12-26 2021-08-13 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąèŻç‰©ç ”ç©¶æ‰€ 1-环深ćŸș-2-(5H-ć’Ș攑[5,1-a]ćŒ‚ćČ據)äč™ćŸș-1-é…źçš„æ‹†ćˆ†
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
JP2020506895A (ja) 2017-01-17 2020-03-05 ăƒœăƒŒăƒ‰ ă‚Șブ レゾェンツ, ă‚¶ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ ăƒ†ă‚­ă‚”ă‚č ă‚·ă‚čテムBoard Of Regents, The University Of Texas System ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒłïŒ’ïŒŒïŒ“âˆ’ă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚ŒăŠă‚ˆăłïŒăŸăŸăŻăƒˆăƒȘプトファンゾă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€ăšă—ăŠæœ‰ç”šăȘćŒ–ćˆç‰©
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
CA3057687A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž 抗icosäżƒæ•ˆćŠ‘æŠ—é«”ćŠć…¶ç”šé€”
SG11201909710XA (en) 2017-04-21 2019-11-28 Kyn Therapeutics Indole ahr inhibitors and uses thereof
ES2899616T3 (es) 2017-04-28 2022-03-14 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 æˆéƒœæ”·ćšé”èŻäžšæœ‰é™ć…Źćž 侀种idoæŠ‘ćˆ¶ć‰‚ćŒ–ćˆç‰©ă€èŻç”šç»„ćˆç‰©ă€ç”šé€”
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. INHIBITORS OF TDO2 AND IDO1
US11827639B2 (en) 2017-06-28 2023-11-28 Genentech, Inc. TDO2 and IDO1 inhibitors
US11236049B2 (en) 2017-06-30 2022-02-01 Bristol-Myers Squibb Company Amorphous and crystalline forms of IDO inhibitors
KR102709265B1 (ko) 2017-07-28 2024-09-23 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
CN111194232B (zh) 2017-08-02 2023-01-31 èŠćŠ ć“„ć€§ć­Š çșłç±łçș§é‡‘ć±žæœ‰æœșć±‚ć’Œé‡‘ć±žæœ‰æœșçșłç±łç‰‡
US11261214B2 (en) 2017-08-04 2022-03-01 Bicycletx Limited Bicyclic peptide ligand specific for CD137
CN109983019B (zh) * 2017-08-08 2021-12-21 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©çš„ćˆ¶ć€‡æ–čæł•
CN109384791B (zh) * 2017-08-09 2020-09-11 æ±Ÿè‹æ’ç‘žćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž 侀种ć’Ș攑ćč¶ćŒ‚ćČć“šç±»èĄç”Ÿç‰©æžžçŠ»çą±çš„æ™¶ćž‹ćŠć…¶ćˆ¶ć€‡æ–čæł•
EP3668880B1 (en) 2017-08-17 2021-10-06 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
CA3073051A1 (en) 2017-08-17 2019-02-21 Ikena Oncology, Inc. Ahr inhibitors and uses thereof
EP3670518A4 (en) 2017-08-18 2021-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC COMPOUND CRYSTALS
JP7209697B2 (ja) 2017-08-31 2023-01-20 ブăƒȘă‚čăƒˆăƒ«ïŒăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒ æŠ—ç™Œć‰€ăšă—ăŠăźç’°çŠ¶ă‚žăƒŒă‚ŻăƒŹă‚Șチド
EP3676279B1 (en) 2017-08-31 2021-12-01 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
EP3676277A1 (en) 2017-08-31 2020-07-08 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 äž­ć›œèŻç§‘ć€§ć­Š ć’Ș攑ćč¶ćŒ‚ćČ據类ido1æŠ‘ćˆ¶ć‰‚ă€ć…¶ćˆ¶ć€‡æ–čæł•揩ćș”甚
US20200261414A1 (en) 2017-09-14 2020-08-20 Lankenau Institute For Medical Research Methods and compositions for the treatment of cancer
EP3684365A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND USES OF SUCH
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3694867A1 (en) 2017-10-10 2020-08-19 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102747388B1 (ko) 2017-10-16 2024-12-26 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
JP7306634B2 (ja) 2017-10-19 2023-07-11 äž€èˆŹç€Ÿć›Łæł•äșșăƒ•ă‚Ąăƒ«ăƒžăƒăƒŹăƒŒăƒ—ăƒ­ă‚žă‚§ă‚Żăƒˆæ”ŻæŽæ©Ÿæ§‹ ïŒ©ïœ„ïœïŒïœ”ïœ„ïœé˜»ćźłć‰€
KR20200074214A (ko) 2017-11-01 2020-06-24 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 암을 ìč˜ëŁŒí•˜ëŠ”ë° ì‚Źìš©í•˜êž° 위한 멎역자ê·č 횚늄작용 항ìČŽ
US11166959B2 (en) 2017-11-06 2021-11-09 Bristol-Myers Squibb Company Isofuranone compounds useful as HPK1 inhibitors
CN111386114A (zh) 2017-11-25 2020-07-07 ç™Ÿæ”Žç„žć·žæœ‰é™ć…Źćž 䜜äžșćČ據èƒș2,3-ćŒćŠ æ°§é…¶çš„é€‰æ‹©æ€§æŠ‘ćˆ¶ć‰‚çš„æ–°éą–è‹Żćč¶ć’Ș攑
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN111886255B (zh) 2018-01-12 2025-04-04 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž 抗tim3æŠ—äœ“ćŠć…¶ç”šé€”
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
JP7217279B2 (ja) 2018-01-15 2023-02-02 ă‚€ăƒ‰ăƒŒă‚·ă‚ą ăƒ•ă‚ĄăƒŒăƒžă‚·ăƒ„ăƒŒăƒ†ă‚Łă‚«ăƒ«ă‚ș ăƒȘミテッド ă‚€ăƒłăƒ‰ăƒŒăƒ«ă‚ąăƒŸăƒł ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚ŒćŠăłïŒćˆăŻăƒˆăƒȘプトファン ïŒ’ïŒŒïŒ“ïŒă‚žă‚Șă‚­ă‚·ă‚ČăƒŠăƒŒă‚Œăźé˜»ćźłć‰€
CN111247119B (zh) * 2018-01-19 2023-02-03 ć››ć·ç§‘äŒŠćšæł°ç”Ÿç‰©ćŒ»èŻè‚Ąä»œæœ‰é™ć…Źćž è„’ç±»ć’Œèƒç±»èĄç”Ÿç‰©ă€ć…¶ćˆ¶ć€‡æ–čæł•ćŠć…¶ćœšćŒ»èŻäžŠçš„ćș”甚
US10793563B2 (en) 2018-01-29 2020-10-06 Merck Patent Gmbh GCN2 inhibitors and uses thereof
KR20200116481A (ko) 2018-01-29 2020-10-12 메넎큏 파텐튾 êČŒì— ëȠ하 Gcn2 얔제제 및 읎의 용도
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
MX2020008791A (es) 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
KR20200130362A (ko) 2018-03-08 2020-11-18 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í•­ì•”ì œëĄœì„œì˜ 시큎늭 디뉎큎레였티드
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
AU2019239747A1 (en) 2018-03-21 2020-10-08 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
CN112218657A (zh) 2018-04-12 2021-01-12 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž Cd73æ‹źæŠ—ć‰‚æŠ—äœ“ć’Œpd-1/pd-l1èœŽæ‹źæŠ—ć‰‚æŠ—äœ“çš„æŠ—ç™Œç»„ćˆç–—æł•
JP2021522211A (ja) 2018-04-16 2021-08-30 ケăƒȘăƒŒă‚ș ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ„ïœïŒ”é˜»ćźłć‰€ăŠă‚ˆăłăăźäœżç”š
WO2019213340A1 (en) 2018-05-03 2019-11-07 Bristol-Myers Squibb Company Uracil derivatives as mer-axl inhibitors
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
ES2950007T3 (es) 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona Ăștiles como activadores de cĂ©lulas T
BR112020026681A2 (pt) 2018-06-27 2021-04-06 Bristol-Myers Squibb Company Compostos naftiridinona substituĂ­dos Ășteis como ativadores de cĂ©lula t
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ĂĄcido
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
US12145927B2 (en) 2018-07-23 2024-11-19 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2020023355A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP3858813A4 (en) * 2018-09-27 2022-06-22 Shenzhen Chipscreen Biosciences Co., Ltd. QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
CN113164780A (zh) 2018-10-10 2021-07-23 æł°æŽ›æ–ŻæČ»ç–—ć…Źćž 抗lapæŠ—äœ“ć˜äœ“ćŠć…¶ç”šé€”
KR20210092769A (ko) 2018-11-16 2021-07-26 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 항-nkg2a 항ìČŽ 및 귞의 용도
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
JP7684947B2 (ja) 2019-03-19 2025-05-28 ăƒ•ăƒłăƒ€ă‚·ă‚Ș プăƒȘバダ ă‚€ăƒłă‚čăƒ†ă‚Łăƒˆă‚„ăƒˆ ディンベă‚čăƒ†ă‚Łă‚Źă‚·ă‚Ș ă‚Șăƒłă‚łăƒ­ă‚žă‚« デ バル スブロン 癌ぼæČ»ç™‚ăźăŸă‚ăźäœ”ç”šç™‚æł•
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US20230295087A1 (en) 2019-05-13 2023-09-21 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
TW202108559A (zh) 2019-05-31 2021-03-01 çŸŽć•†é†«è‚ŻçŽè…«ç˜€ć­žć…Źćž TeadæŠ‘ćˆ¶ćŠ‘ćŠć…¶ç”šé€”
EP3997083A1 (en) 2019-07-11 2022-05-18 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos Ăștiles como activadores de cĂ©lulas t
EP4027995A4 (en) 2019-09-13 2023-08-23 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND THEIR APPLICATIONS
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
KR20220103753A (ko) 2019-11-19 2022-07-22 ëžŒëŠŹìŠ€í†š-마읎얎슀 슀큅 컎퍌니 í—ŹëŠŹì˜€ìŠ€ 닚백질의 ì–”ì œì œëĄœì„œ 유용한 í™”í•©ëŹŒ
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
CA3159071A1 (en) 2019-11-26 2021-06-03 Tamar I. ROSENBAUM Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
CN111333653A (zh) * 2019-12-16 2020-06-26 ć±±äžœć€§ć­Š 侀种icdèŻ±ćŻŒć‰‚-idoæŠ‘ćˆ¶ć‰‚çŒ€ćˆç‰©ćŠćˆ¶ć€‡æ–čæł•䞎ćș”甚
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
MX2022007576A (es) 2019-12-17 2022-09-23 Kymera Therapeutics Inc Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicĂ­clicos sustituidos Ăștiles como activadores de cĂ©lulas t
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
IL294150A (en) 2019-12-23 2022-08-01 Kymera Therapeutics Inc Smarca joints and their uses
BR112022012222A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Derivados de piperazina substituĂ­dos Ășteis como ativadores de cĂ©lulas t
IL294269A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinolinonyl piperazine compounds useful as t cell activators
ES3038401T3 (en) 2019-12-23 2025-10-13 Bristol Myers Squibb Co Substituted quinazolinyl compounds useful as t cell activators
CA3166898A1 (en) 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
BR112022013494A2 (pt) 2020-01-07 2022-09-13 Hifibio Hk Ltd Anticorpo anti-galectina-9 e usos do mesmo
EP4090663A1 (en) 2020-01-15 2022-11-23 Blueprint Medicines Corporation Map4k1 inhibitors
AU2021230289A1 (en) 2020-03-03 2022-09-29 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
US20230140384A1 (en) 2020-03-09 2023-05-04 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteĂ­na de homĂłlogo de ratĂłn de minuto 2 (mdm2) y usos de los mismos.
TW202140441A (zh) 2020-03-23 2021-11-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ćŸș異ćČć“šć•‰ćŒ–ćˆç‰©
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202210483A (zh) 2020-06-03 2022-03-16 çŸŽć•†ć‡±éș„æ‹‰é†«ç™‚ć…Źćž Iraké™è§ŁćŠ‘äč‹ç”æ™¶ćž‹
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
CN111803635B (zh) * 2020-06-17 2023-03-14 äž­ć›œćŒ»ć­Šç§‘ć­Šé™ąćŸșçĄ€ćŒ»ć­Šç ”ç©¶æ‰€ ć°ćˆ†ć­æŠ‘ćˆ¶ć‰‚ćœšæČ»ç–—ć‘Œćžé“ç—…æŻ’æ€§è‚ș炎侊的ćș”甚
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
KR20230044480A (ko) 2020-07-30 2023-04-04 ìčŽìŽë©”띌 쎄띌퓚틱슀 ìžìœ”íŹë ˆìŽí‹°ë“œ ëŒì—°ëł€ìŽ ëŠŒí”„ìą…ì˜ ìč˜ëٌ ë°©ëȕ
IL300537A (en) 2020-08-10 2023-04-01 Gv20 Therapeutics Llc Compositions and methods for treating autoimmune diseases and cancer by targeting IGSF8
EP4196792A1 (en) 2020-08-17 2023-06-21 BicycleTX Limited Bicycle conjugates specific for nectin-4 and uses thereof
US20230416382A1 (en) 2020-10-14 2023-12-28 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
CA3200814A1 (en) 2020-12-02 2022-06-09 Alfredo C. Castro Tead inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN116964050A (zh) 2020-12-16 2023-10-27 æˆˆèšé»˜ç”Ÿç‰©æœćŠĄć…Źćž ćŻç”šäœœtç»†èƒžæż€æŽ»ć‰‚çš„ćŒ–ćˆç‰©
AU2021413371A1 (en) 2020-12-30 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
AU2022215844A1 (en) 2021-02-02 2023-09-14 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
CN117098757A (zh) 2021-02-02 2023-11-21 é‡Œç±łèŻșç”Ÿç‰©ç§‘ć­Šæœ‰é™ć…Źćž Gpr84æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
CN117120090A (zh) 2021-02-12 2023-11-24 æž—äŒŻćŁ«èšéĄżć…Źćž Hpk1æ‹źæŠ—ć‰‚ć’Œć…¶ç”šé€”
AU2022221124A1 (en) 2021-02-12 2023-08-03 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
AU2022220043A1 (en) 2021-02-15 2023-08-31 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022220869A1 (en) 2021-02-15 2023-08-24 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
EP4052705A1 (en) 2021-03-05 2022-09-07 UniversitÀt Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
US20240091202A1 (en) 2021-03-05 2024-03-21 UniversitÀt Basel Compositions for the treatment of ebv associated diseases or conditions
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024510176A (ja) 2021-03-08 2024-03-06 ăƒ–ăƒ«ăƒŒăƒ—ăƒȘント ăƒĄăƒ‡ă‚Łă‚·ăƒłă‚ș ă‚łăƒŒăƒăƒŹă‚€ă‚·ăƒ§ăƒł ïŒ­ïœïœïŒ”ïœ‹ïŒ‘é˜»ćźłć‰€
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
JP2024514530A (ja) 2021-04-02 2024-04-02 ă‚¶ ăƒȘăƒŒă‚žă‚§ăƒłăƒ„ ă‚Șブ ă‚¶ ăƒŠăƒ‹ăƒăƒŒă‚·ăƒ†ă‚Ł ă‚Șブ ă‚«ăƒȘăƒ•ă‚©ăƒ«ăƒ‹ă‚ą ćˆ‡æ–­ćž‹ïœƒïœ„ïœƒïœïŒ‘ă«ćŻŸă™ă‚‹æŠ—äœ“ăŠă‚ˆăłăăźäœżç”š
MX2023011408A (es) 2021-04-05 2024-01-18 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
AR125298A1 (es) 2021-04-06 2023-07-05 Bristol Myers Squibb Co Compuestos de oxoisoindolina sustituidos con piridinilo
EP4319756A4 (en) 2021-04-09 2025-02-26 Nimbus Clio, Inc. CBL-B MODULATORS AND USES THEREOF
JP2024514879A (ja) 2021-04-16 2024-04-03 ă‚€ă‚±ăƒŠ ă‚Șăƒłă‚łăƒ­ă‚žăƒŒïŒŒ ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ­ïœ…ïœ‹é˜»ćźłć‰€ćŠăłăăźäœżç”š
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
AU2022312496A1 (en) 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
TW202321238A (zh) 2021-07-15 2023-06-01 çŸŽć•†çșœćœ–è—„擁慬揾 ïŒ­ïœïœïŒ”ïœ‹ïŒ‘æŠ‘ćˆ¶ćŠ‘
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク ă‚»ăƒ©ăƒ”ăƒ„ăƒŒăƒ†ă‚Łă‚Żă‚č ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïœ…ïŒ©ïŒŠïŒ”ïŒ„é˜»ćźłć‰€ćŠăłăăźäœżç”š
CN118302168A (zh) 2021-10-29 2024-07-05 懯éșŠæ‹‰ćŒ»ç–—ć…Źćž Irak4é™è§Łć‰‚ć’Œć…¶ćˆ¶ć€‡
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
JP2025503312A (ja) 2022-02-01 2025-01-30 ă‚ąăƒ«ăƒ“ăƒŠă‚č・ă‚ȘăƒšăƒŹăƒŒă‚·ăƒ§ăƒłă‚șăƒ»ă‚€ăƒłă‚łăƒŒăƒăƒŹă‚€ăƒ†ăƒƒăƒ‰ ïŒ€ïœ‡ïœ‹æš™çš„ćŒ–ćŒ–ćˆç‰©ăŠă‚ˆăłăăźäœżç”š
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023230205A1 (en) 2022-05-25 2023-11-30 Ikena Oncology, Inc. Mek inhibitors and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
KR20250057800A (ko) 2022-08-02 2025-04-29 멬믾널 ë°”ìŽì˜€ì‚ŹìŽì–žì‹œìŠ€ 멬믾티드 í—€í…ŒëĄœì•„ëŠŽ ìčŽëł”슀아마읎드 및 ꎀ렚 gpr84 êžží•­ì œ 및 읎의 용도
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
WO2024036100A1 (en) 2022-08-08 2024-02-15 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
TW202417439A (zh) 2022-08-11 2024-05-01 ç‘žćŁ«ć•†è”«ć­šć­Ÿæ‹‰çŸ…è‚Ąä»œć…Źćž é›™ç’°ć››æ°«ć™»ć–ć‘ŻèĄç”Ÿç‰©
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
MA71728A (fr) 2022-08-11 2025-05-30 F. Hoffmann-La Roche Ag Dérivés bicycliques de tétrahydrothiazépine
JP2025526727A (ja) 2022-08-11 2025-08-15 ă‚šăƒ•ăƒ»ăƒ›ăƒ•ăƒžăƒłïŒăƒ©ăƒ»ăƒ­ă‚·ăƒ„ăƒ»ă‚ąă‚Żăƒă‚§ăƒłă‚Čă‚Œăƒ«ă‚·ăƒŁăƒ•ăƒˆ äșŒç’°ćŒăƒ†ăƒˆăƒ©ăƒ’ăƒ‰ăƒ­ăƒă‚ąă‚Œăƒ”ăƒłèȘ˜ć°Žäœ“
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 ćčżć·žćž‚è”ç‘žćˆ¶èŻæœ‰é™ć…Źćž äž€ç§çŽŻçŁ·è…șè‹·æ‚èŽšçš„ćˆ¶ć€‡æ–čæł•
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN121057732A (zh) 2023-05-08 2025-12-02 ç™Ÿæ—¶çŸŽæ–œèŽ”ćźć…Źćž ç»ć–ä»Łçš„è‹ŻćŸșć™ć”‘é…źćŒ–ćˆç‰©
AU2024269298A1 (en) 2023-05-10 2025-11-27 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
WO2024264017A2 (en) 2023-06-23 2024-12-26 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133696A1 (es) 2023-09-02 2025-10-22 Bristol Myers Squibb Co Compuestos de fenil oxooxazolil piperidinadiona sustituida
TW202525792A (zh) 2023-09-13 2025-07-01 çŸŽć•†ćż…æČ»ćŠ„çŸŽé›…ćČè°·æŻ”ć…Źćž ç¶“ć–ä»Łäč‹ćŽæ°§ç•°ćČ據敉ćŸșć“Œć•¶ïŒïŒ’ïŒŒïŒ–ïŒäșŒé…źćŒ–ćˆç‰©
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
CN119707950A (zh) * 2024-12-24 2025-03-28 æ— é”Ąćž‚ć—äșŹć€§ć­Šé”Ąć±±ćș”ç”šç”Ÿç‰©æŠ€æœŻç ”ç©¶æ‰€ 侀种甹äșŽć…ç–«è›‹ç™œé¶ć‘é™è§Łçš„ć”Œćˆäœ“ćŠć…¶ćˆ¶ć€‡æ–čæł•ć’Œćș”甚

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584013A (en) 1983-05-18 1986-04-22 Ciba-Geigy Corporation Cyclohexanedionecarboxylic acid derivatives with herbicidal and plant growth regulating properties
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
AU1628699A (en) 1997-12-05 1999-06-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
US20030194803A1 (en) 2002-04-12 2003-10-16 Mellor Andrew L. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
EP1606285A4 (en) 2003-03-27 2009-03-18 Lankenau Inst Medical Res NEW IDO HEMMER AND APPLICATION PROCEDURES
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
DK2559690T3 (en) * 2005-05-10 2016-04-25 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of use thereof
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 GrĂŒnenthal GmbH Substituierte Amid-Derivate
CA2932121A1 (en) * 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
CA2709202C (en) 2007-12-19 2013-04-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CN102083429B (zh) * 2008-04-24 2014-05-28 新联ćŸș曠慬揾 IdoæŠ‘ćˆ¶ć‰‚
NZ590268A (en) 2008-07-08 2012-11-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
NO2694640T3 (enExample) * 2011-04-15 2018-03-17
KR20150087400A (ko) 2012-11-20 2015-07-29 ëČ„í…ìŠ€ 파마슈티ìčŒìŠ€ ìžìœ”íŹë ˆìŽí‹°ë“œ ìžëŒì•„ëŻŒ 2,3-디옄시êČŒë‚˜ì œì˜ ì–”ì œì œëĄœì„œ 유용한 í™”í•©ëŹŒ
EA201591610A1 (ru) 2013-03-14 2015-12-30 ĐšŃƒŃ€Đ°ĐŽĐ”ĐČ Đ€Đ°Ń€ĐŒĐ° ПраĐčĐČот ЛтЮ. Đ˜ĐœĐłĐžĐ±ĐžŃ‚ĐŸŃ€Ń‹ ĐșĐžĐœŃƒŃ€Đ”ĐœĐžĐœĐŸĐČĐŸĐłĐŸ путо
BR112015022588A2 (pt) 2013-03-14 2017-07-18 Newlink Genetics Corp composto, composição farmacĂȘutica, e, mĂ©todo para tratamento de imunossupressĂŁo em um indivĂ­duo
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
BR112015021999A8 (pt) 2013-03-15 2019-12-03 Bristol Myers Squibb Co inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacĂȘutica, e mĂ©todo para inibir a atiavidade de indoleamina 2,3-dioxigenase
MA38483A1 (fr) 2013-03-15 2018-02-28 Bristol Myers Squibb Co Inhibiteurs de l'ido
JP2016528197A (ja) 2013-07-01 2016-09-15 ブăƒȘă‚čăƒˆăƒ«âˆ’ăƒžă‚€ăƒ€ăƒŒă‚ș ă‚čă‚Żă‚€ăƒ– ă‚«ăƒłăƒ‘ăƒ‹ăƒŒïŒąïœ’ïœ‰ïœ“ïœ”ïœïœŒâˆ’ïŒ­ïœ™ïœ…ïœ’ïœ“ ïŒłïœ‘ïœ•ïœ‰ïœ‚ïœ‚ ïŒŁïœïœïœïœïœŽïœ™ ïŒ©ïœ„ïœé˜»ćźłć‰€
WO2015006520A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors

Also Published As

Publication number Publication date
JP5837673B2 (ja) 2015-12-24
US10233190B2 (en) 2019-03-19
AU2012242871B2 (en) 2014-09-11
IL241846A (en) 2016-06-30
PL3018132T3 (pl) 2018-05-30
US9260434B2 (en) 2016-02-16
CN105111210B (zh) 2018-10-09
AU2016277574B2 (en) 2018-04-19
CN103547579A (zh) 2014-01-29
RU2017107026A3 (enExample) 2019-01-23
SI3018132T1 (en) 2018-04-30
AU2018202706A1 (en) 2018-05-10
ES2660831T3 (es) 2018-03-26
CA2833296A1 (en) 2012-10-18
RS56992B1 (sr) 2018-05-31
EP3348558A1 (en) 2018-07-18
DK2697227T3 (en) 2016-04-25
US20160002249A1 (en) 2016-01-07
DK3018132T3 (en) 2018-03-12
JP2014511876A (ja) 2014-05-19
AU2014274564B2 (en) 2016-10-06
AU2012242871C1 (en) 2017-02-02
US9388191B2 (en) 2016-07-12
AU2016277574A1 (en) 2017-01-12
PT3018132T (pt) 2018-03-09
CN105111210A (zh) 2015-12-02
PE20181023A1 (es) 2018-06-27
EP2697227A1 (en) 2014-02-19
BR112013026494A2 (pt) 2016-12-27
HRP20180335T1 (hr) 2018-04-20
CY1117440T1 (el) 2017-04-26
EP3018132A1 (en) 2016-05-11
SI2697227T1 (sl) 2016-06-30
US20160362412A1 (en) 2016-12-15
HK1256355A1 (en) 2019-09-20
JP2016029092A (ja) 2016-03-03
IL246515B (en) 2018-08-30
WO2012142237A8 (en) 2012-11-22
IL228862A0 (en) 2013-12-31
JP2017149769A (ja) 2017-08-31
RU2013150811A (ru) 2015-05-20
CL2013002990A1 (es) 2014-07-04
NZ708090A (en) 2016-12-23
RS54723B1 (sr) 2016-08-31
CN103547579B (zh) 2017-02-15
HK1223371A1 (en) 2017-07-28
KR102164443B1 (ko) 2020-10-12
HRP20160369T1 (hr) 2016-06-03
NZ616457A (en) 2015-05-29
JP2015061877A (ja) 2015-04-02
AU2012242871A1 (en) 2013-10-31
AU2014274564A1 (en) 2015-01-22
MX2013012021A (es) 2014-07-10
JP6145491B2 (ja) 2017-06-14
KR20140059167A (ko) 2014-05-15
LT3018132T (lt) 2018-03-26
RU2613579C2 (ru) 2017-03-17
IL228862A (en) 2015-10-29
HUE027316T2 (en) 2016-10-28
MX340442B (es) 2016-07-08
ES2569665T3 (es) 2016-05-12
US20190225618A1 (en) 2019-07-25
US20180118753A1 (en) 2018-05-03
PE20141124A1 (es) 2014-09-06
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
IL241846A0 (en) 2015-11-30
NZ723271A (en) 2018-03-23
HUE038586T2 (hu) 2018-10-29
CO6862146A2 (es) 2014-02-10
AU2012242871A8 (en) 2013-11-21
HK1193822A1 (zh) 2014-10-03
WO2012142237A1 (en) 2012-10-18
EP2697227B1 (en) 2016-02-03
RU2017107026A (ru) 2019-01-23
US20140066625A1 (en) 2014-03-06
US9850248B2 (en) 2017-12-26
CA2833296C (en) 2020-12-08
EP3018132B1 (en) 2017-12-13
NO2694640T3 (enExample) 2018-03-17

Similar Documents

Publication Publication Date Title
IL246515B (en) Imidazole derivatives are designed for use as ido inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201305612B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
SG10201601802YA (en) Dispiropyrrolidine derivatives
IL233366A (en) Tetra- or phentocyclo-pyridopathalazines are digested as parp inhibitors
IL227252A0 (en) Aminodihydrothiazine history from sisterhood
ZA201305826B (en) Substituted amminobutyric derivatives as neprilysin inhibitors
IL228949A0 (en) History of pyrazolospiroctone for use as acetyl-CoA carboxylase inhibitors
IL258704B (en) History of hydantoins used as kv3 inhibitors
IL233365A0 (en) Tetra or pentacyclic dihydrodiazepinocarbazolones are conjugated as parp inhibitors
AP3529A (en) Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
IL247639B (en) History of heteroaryl piperidine
IL229990A0 (en) History of n-oxypyrazolo-triazapine-dione
EP2744788A4 (en) BENZOPIPERAZINE DERIVATIVES AS CETP INHIBITORS
EP2703403A4 (en) imidazole
SI2766342T1 (sl) Derivati fenil-gvanidina
ZA201308049B (en) 3-ureidoisoquinolin-8-yl derivatives
PT2721009E (pt) Derivados de pirazole Ășteis como inibidores de aldosterona sintase
HK1186463A (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
ZA201209319B (en) Cyclopropyl-indole derivatives
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives